MedTrace Logo

Qingdao: Insulin Pump Follow-Up Program

NCT02655666 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2019-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to observe/ collect clinical data, subject users' feedback, and device data to better understand the real-life usage and acceptance of the 722 Pump in type 1 diabetes subjects,\<18 years of age, and the role of insulin pump therapy in Qingdao,China.

Conditions

Sponsors & Collaborators

  • Medtronic Diabetes

    lead INDUSTRY

Principal Investigators

  • Tang Li · The Affiliated Hospital of Qingdao University

  • chunbin Wang · Chinese People's Liberation Army 401 Hospital

  • Yamie Zhu · Qingdao Endocrine and Diabetes Hospital

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655666 on ClinicalTrials.gov